Market Overview:
The global natalizumab drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of multiple sclerosis and Crohn's disease, rising demand for better treatment options, and growing awareness about natalizumab drugs. The global natalizumab drug market is segmented on the basis of type into multiple sclerosis and Crohn's disease. The multiple sclerosis segment is expected to account for the majority share of the global natalizumab drug market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The Crohn's disease segment is projected to grow at a CAGR of XX% during the same period.
Product Definition:
Natalizumab is used to treat multiple sclerosis (MS). It helps reduce flare-ups and slows the progression of the disease.
Multiple Sclerosis:
Multiple sclerosis is a chronic disease of the central nervous system that affects all the organs. The most common symptoms include visual loss, tingling or pain in extremities, and muscle stiffness. There are two types of multiple sclerosis namely; First (primary) multiple sclerosis and Second (relapsing-remitting) multiple sclerosis. Natalizumab is used for both types of Multiple Sclerosis patient which includes an attack as well as prevention from future attacks by reducing relapses to an extent.
Crohn's Disease:
Crohn's disease is a chronic, incurable, and painful condition of the digestive system. It has two main symptoms - abdominal pain and diarrhea. Other symptoms include rectal bleeding, weight loss, blood in stool or urine and fatigue. The exact cause of Crohn's disease is unknown but it may be due to genetic factors or environmental factors such as infection from bacteria in the soil (gut flora), viral infection during pregnancy etc.
Application Insights:
The global natalizab drug market is segmented by application into hospital, retail and drugs stores. The hospital segment dominated the market in 2017 due to factors such as high prevalence of patients suffering from multiple sclerosis and Crohn¢â‚¬â„¢s disease across the globe. According to data published by WHO, globally around 400,000 people are diagnosed with MS every year while about 100,000 individuals are estimated to be suffering from CD. Thus, increasing number of patients with these conditions is expected to contribute towards growth in demand for natalizumab drug over the forecast period.
On the other hand, Crohn¢â‚¬â„¢s disease accounted for a significant share in 2017 owing to presence of several treatment options available for this condition such as immunosuppressants and biologics like rituximab that help reduce inflammation & pain caused by this condition without any reported side effects so far.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in the prevalence of inflammatory bowel disease and multiple sclerosis. In addition, increasing awareness about natalizumab among patients is expected to drive growth over the forecast period. The U.S., which accounted for more than 80% share of North America market, is estimated to remain dominant throughout the forecast period due to an increase in approvals and launch of new products by companies operating within this region.
Europe followed North America with a significant share as several companies are based within this region while others have their headquarters here or they conduct most of their business outside Europe through European subsidiaries/affiliates (i.e., subsidiary/affiliate agreements). Companies headquartered within Europe include Aranesp GmbH & Co., Ltd.; Teva Pharmaceuticals USA; Pfizer Inc.
Growth Factors:
- Increasing incidence of multiple sclerosis (MS)
- Rising demand for better treatment options for MS
- Growing awareness about Natalizumab Drug therapy among physicians and patients
- Technological advancements in the field of Natalizumab Drug therapy
- Availability of reimbursement for Natalizumab Drug therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Natalizumab Drug Market Research Report
By Type
Multiple Sclerosis, Crohn's Disease
By Application
Hospital, Drugs Stores
By Companies
Biogen, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Natalizumab Drug Market Report Segments:
The global Natalizumab Drug market is segmented on the basis of:
Types
Multiple Sclerosis, Crohn's Disease
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Biogen
Highlights of The Natalizumab Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Multiple Sclerosis
- Crohn's Disease
- By Application:
- Hospital
- Drugs Stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Natalizumab Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Natalizumab is a drug used to treat multiple sclerosis (MS). It works by reducing the number of attacks in people with MS.
Some of the major players in the natalizumab drug market are Biogen, Biogen.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Natalizumab Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Natalizumab Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Natalizumab Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Natalizumab Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Natalizumab Drug Market Size & Forecast, 2020-2028
4.5.1 Natalizumab Drug Market Size and Y-o-Y Growth
4.5.2 Natalizumab Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Multiple Sclerosis
5.2.2 Crohn's Disease
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Natalizumab Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Natalizumab Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Multiple Sclerosis
9.6.2 Crohn's Disease
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Multiple Sclerosis
10.6.2 Crohn's Disease
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Multiple Sclerosis
11.6.2 Crohn's Disease
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Multiple Sclerosis
12.6.2 Crohn's Disease
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Multiple Sclerosis
13.6.2 Crohn's Disease
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Natalizumab Drug Market: Competitive Dashboard
14.2 Global Natalizumab Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Biogen
